首页 > 最新文献

Advances in Rheumatology最新文献

英文 中文
Lyme disease and Whipple’s disease: a comprehensive review for the rheumatologist 莱姆病与威普尔氏病:风湿病学家的全面回顾
IF 2.3 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-03-04 DOI: 10.1186/s42358-024-00359-x
Henrique Ayres Mayrink Giardini, Fabricio Souza Neves, Ivanio Alves Pereira, Rafael Alves Cordeiro
Despite their rarity, Lyme disease and Whipple’s disease are of significant importance in rheumatology, as both can manifest as chronic arthritis, presenting challenges in the differential diagnosis of inflammatory arthropathies. In Lyme disease, arthritis typically emerges as a late manifestation, usually occurring six months after the onset of erythema migrans. The predominant presentation involves mono- or oligoarthritis of large joints, with a chronic or remitting-recurrent course. Even with appropriate antimicrobial treatment, arthritis may persist due to inadequate immunological control triggered by the disease. In contrast, Whipple’s disease may present with a migratory and intermittent seronegative poly- or oligoarthritis of large joints, preceding classic gastrointestinal symptoms by several years. Both disorders, particularly Whipple’s disease, can be misdiagnosed as more common autoimmune rheumatic conditions such as rheumatoid arthritis and spondyloarthritis. Epidemiology is crucial in suspecting and diagnosing Lyme disease, as the condition is transmitted by ticks prevalent in specific areas of the United States, Europe, and Asia. On the contrary, the causative agent of Whipple’s disease is widespread in the environment, yet invasive disease is rare and likely dependent on host genetic factors. In addition to erythema migrans in Lyme disease and gastrointestinal manifestations in Whipple’s disease, neurological and cardiac involvement can further complicate the course of both. This article offers a comprehensive review of the epidemiological, pathophysiological, clinical, and therapeutic aspects of both diseases.
莱姆病和惠普尔病尽管罕见,但在风湿病学中却具有重要意义,因为这两种疾病都可以表现为慢性关节炎,给炎症性关节病的鉴别诊断带来了挑战。在莱姆病中,关节炎通常是晚期表现,通常在迁延性红斑发病后六个月出现。主要表现为大关节的单关节炎或少关节炎,病程为慢性或缓解-复发。即使接受了适当的抗菌治疗,由于疾病引发的免疫控制不足,关节炎仍可能持续存在。相反,Whipple's 病可能表现为迁延性和间歇性血清阴性大关节多关节炎或少关节炎,比典型的胃肠道症状早数年。这两种疾病,尤其是惠普尔病,都可能被误诊为更常见的自身免疫性风湿病,如类风湿性关节炎和脊柱关节炎。流行病学是怀疑和诊断莱姆病的关键,因为该病是由流行于美国、欧洲和亚洲特定地区的蜱传播的。相反,惠普尔病的病原体在环境中广泛存在,但侵入性疾病却很少见,而且很可能取决于宿主的遗传因素。除了莱姆病的迁徙性红斑和惠普尔病的胃肠道表现外,神经系统和心脏受累也会使两者的病程进一步复杂化。本文对这两种疾病的流行病学、病理生理学、临床和治疗方面进行了全面综述。
{"title":"Lyme disease and Whipple’s disease: a comprehensive review for the rheumatologist","authors":"Henrique Ayres Mayrink Giardini, Fabricio Souza Neves, Ivanio Alves Pereira, Rafael Alves Cordeiro","doi":"10.1186/s42358-024-00359-x","DOIUrl":"https://doi.org/10.1186/s42358-024-00359-x","url":null,"abstract":"Despite their rarity, Lyme disease and Whipple’s disease are of significant importance in rheumatology, as both can manifest as chronic arthritis, presenting challenges in the differential diagnosis of inflammatory arthropathies. In Lyme disease, arthritis typically emerges as a late manifestation, usually occurring six months after the onset of erythema migrans. The predominant presentation involves mono- or oligoarthritis of large joints, with a chronic or remitting-recurrent course. Even with appropriate antimicrobial treatment, arthritis may persist due to inadequate immunological control triggered by the disease. In contrast, Whipple’s disease may present with a migratory and intermittent seronegative poly- or oligoarthritis of large joints, preceding classic gastrointestinal symptoms by several years. Both disorders, particularly Whipple’s disease, can be misdiagnosed as more common autoimmune rheumatic conditions such as rheumatoid arthritis and spondyloarthritis. Epidemiology is crucial in suspecting and diagnosing Lyme disease, as the condition is transmitted by ticks prevalent in specific areas of the United States, Europe, and Asia. On the contrary, the causative agent of Whipple’s disease is widespread in the environment, yet invasive disease is rare and likely dependent on host genetic factors. In addition to erythema migrans in Lyme disease and gastrointestinal manifestations in Whipple’s disease, neurological and cardiac involvement can further complicate the course of both. This article offers a comprehensive review of the epidemiological, pathophysiological, clinical, and therapeutic aspects of both diseases.","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"28 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140026415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eye signs as a novel risk predictor in pulmonary arterial hypertension associated with systemic lupus erythematosus. 眼征是系统性红斑狼疮相关肺动脉高压的新型风险预测因子。
IF 2 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-02-29 DOI: 10.1186/s42358-024-00356-0
Jianbin Li, Jiangbiao Xiong, Pengcheng Liu, Yilin Peng, Shuang Cai, Xia Fang, Shujiao Yu, Jun Zhao, Rui Wu

Objective: To investigate the role of eye signs in predicting poor outcomes in systemic lupus erythematosus (SLE) patients with pulmonary arterial hypertension (PAH).

Methods: This prospective observational study recruited patients diagnosed with SLE-PAH from Jan. 2021 to Dec. 2021 at the First Affiliated Hospital of Nanchang University; those with other potential causes of PAH were excluded. The evaluation of various parameters, such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP), 6-minute walking distance (6MWD), World Health Organization functional class (WHO-FC), echocardiography, and risk stratification based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines, was conducted at intervals of every 1-3 months, and a 6-month follow-up period was observed. The primary outcome measure considered improvement if there was a decline in the risk stratification grade at the end point and unimproved if there was no decline. Conjunctival microvascular images were observed and recorded.

Results: A total of 29 SLE-PAH patients were enrolled, comprising 12 in the improved group and 17 in the nonimproved group. All SLE-PAH patients showed various manifestations of eye signs, including vessel twisting, dilation, ischaemic areas, haemorrhages, reticulum deformity, and wound spots. The nonimproved group exhibited significantly lower vessel density (VD) and microvascular flow index (MFI) of conjunctival microvascular images than the improved group. Correlation analysis revealed that VD displayed a negative correlation with the WHO-FC (r = -0.413, p = 0.026) and NT-proBNP (r = -0.472, p = 0.010), as well as a positive correlation with the 6MWD (r = 0.561, p = 0.002). Similarly, MFI exhibited a negative correlation with WHO-FC (r = -0.408, p = 0.028) and NT-proBNP (r = -0.472, p = 0.010) and a positive correlation with 6MWD (r = 0.157, p = 0.004). Multivariate logistic regression analysis indicated that VD (OR 10.11, 95% CI 1.95-52.36), MFI (OR 7.85, 95% CI 1.73-35.67), NT-proBNP, and 6MWD were influential factors in predicting the prognostic improvement of SLE-PAH patients. ROC curve analysis demonstrated that VD, MFI, 6MWD, and NT-proBNP (with respective AUC values of 0.83, 0.83, 0.76, and 0.90, respectively) possessed a sensitivity and specificity of 75 and 100%, as well as 83 and 100%, respectively. Regarding prognostic prediction, VD and MFI exhibited higher sensitivity than 6MWD, whereas MFI displayed higher sensitivity and specificity than NT-proBNP.

Conclusion: SLE-PAH can lead to various conjunctival microvascular manifestations in which vascular density and microvascular flow index can be used to assess cardiopulmonary function and predict therapeutic efficacy and prognosis in SLE-PAH patients.

目的探讨眼部体征在预测系统性红斑狼疮(SLE)肺动脉高压(PAH)患者不良预后中的作用:这项前瞻性观察研究招募了2021年1月至2021年12月在南昌大学第一附属医院确诊的系统性红斑狼疮-PAH患者,排除了其他潜在原因导致的PAH患者。每隔1-3个月对N端脑钠肽前体(NT-proBNP)、6分钟步行距离(6MWD)、世界卫生组织功能分级(WHO-FC)、超声心动图等各项指标进行评估,并根据2015年欧洲心脏病学会(ESC)/欧洲呼吸学会(ERS)指南进行风险分层,随访6个月。如果风险分层等级在终点时有所下降,则认为主要结果有所改善;如果风险分层等级没有下降,则认为主要结果没有改善。对结膜微血管图像进行了观察和记录:共有 29 名系统性红斑狼疮-PAH 患者接受了治疗,其中改善组 12 人,未改善组 17 人。所有系统性红斑狼疮-PAH 患者都出现了各种眼部症状,包括血管扭曲、扩张、缺血区、出血、网状变形和伤口斑点。未改善组结膜微血管图像的血管密度(VD)和微血管流量指数(MFI)明显低于改善组。相关性分析表明,VD 与 WHO-FC(r = -0.413,p = 0.026)和 NT-proBNP(r = -0.472,p = 0.010)呈负相关,与 6MWD 呈正相关(r = 0.561,p = 0.002)。同样,MFI与WHO-FC(r = -0.408,p = 0.028)和NT-proBNP(r = -0.472,p = 0.010)呈负相关,与6MWD(r = 0.157,p = 0.004)呈正相关。多变量逻辑回归分析表明,VD(OR 10.11,95% CI 1.95-52.36)、MFI(OR 7.85,95% CI 1.73-35.67)、NT-proBNP 和 6MWD 是预测 SLE-PAH 患者预后改善的影响因素。ROC 曲线分析表明,VD、MFI、6MWD 和 NT-proBNP(AUC 值分别为 0.83、0.83、0.76 和 0.90)的敏感性和特异性分别为 75%和 100%,以及 83%和 100%。在预后预测方面,VD和MFI比6MWD表现出更高的灵敏度,而MFI比NT-proBNP表现出更高的灵敏度和特异性:结论:SLE-PAH可导致各种结膜微血管表现,其中血管密度和微血管流量指数可用于评估SLE-PAH患者的心肺功能并预测疗效和预后。
{"title":"Eye signs as a novel risk predictor in pulmonary arterial hypertension associated with systemic lupus erythematosus.","authors":"Jianbin Li, Jiangbiao Xiong, Pengcheng Liu, Yilin Peng, Shuang Cai, Xia Fang, Shujiao Yu, Jun Zhao, Rui Wu","doi":"10.1186/s42358-024-00356-0","DOIUrl":"10.1186/s42358-024-00356-0","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role of eye signs in predicting poor outcomes in systemic lupus erythematosus (SLE) patients with pulmonary arterial hypertension (PAH).</p><p><strong>Methods: </strong>This prospective observational study recruited patients diagnosed with SLE-PAH from Jan. 2021 to Dec. 2021 at the First Affiliated Hospital of Nanchang University; those with other potential causes of PAH were excluded. The evaluation of various parameters, such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP), 6-minute walking distance (6MWD), World Health Organization functional class (WHO-FC), echocardiography, and risk stratification based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines, was conducted at intervals of every 1-3 months, and a 6-month follow-up period was observed. The primary outcome measure considered improvement if there was a decline in the risk stratification grade at the end point and unimproved if there was no decline. Conjunctival microvascular images were observed and recorded.</p><p><strong>Results: </strong>A total of 29 SLE-PAH patients were enrolled, comprising 12 in the improved group and 17 in the nonimproved group. All SLE-PAH patients showed various manifestations of eye signs, including vessel twisting, dilation, ischaemic areas, haemorrhages, reticulum deformity, and wound spots. The nonimproved group exhibited significantly lower vessel density (VD) and microvascular flow index (MFI) of conjunctival microvascular images than the improved group. Correlation analysis revealed that VD displayed a negative correlation with the WHO-FC (r = -0.413, p = 0.026) and NT-proBNP (r = -0.472, p = 0.010), as well as a positive correlation with the 6MWD (r = 0.561, p = 0.002). Similarly, MFI exhibited a negative correlation with WHO-FC (r = -0.408, p = 0.028) and NT-proBNP (r = -0.472, p = 0.010) and a positive correlation with 6MWD (r = 0.157, p = 0.004). Multivariate logistic regression analysis indicated that VD (OR 10.11, 95% CI 1.95-52.36), MFI (OR 7.85, 95% CI 1.73-35.67), NT-proBNP, and 6MWD were influential factors in predicting the prognostic improvement of SLE-PAH patients. ROC curve analysis demonstrated that VD, MFI, 6MWD, and NT-proBNP (with respective AUC values of 0.83, 0.83, 0.76, and 0.90, respectively) possessed a sensitivity and specificity of 75 and 100%, as well as 83 and 100%, respectively. Regarding prognostic prediction, VD and MFI exhibited higher sensitivity than 6MWD, whereas MFI displayed higher sensitivity and specificity than NT-proBNP.</p><p><strong>Conclusion: </strong>SLE-PAH can lead to various conjunctival microvascular manifestations in which vascular density and microvascular flow index can be used to assess cardiopulmonary function and predict therapeutic efficacy and prognosis in SLE-PAH patients.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"15"},"PeriodicalIF":2.0,"publicationDate":"2024-02-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory cytokines and their potential role in Sjogren's syndrome risk: insights from a mendelian randomization study. 炎性细胞因子及其在 Sjogren's 综合征风险中的潜在作用:一项孟德尔随机研究的启示。
IF 2 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-02-16 DOI: 10.1186/s42358-024-00354-2
Wenbin Shi, Yuli Xu, Anan Zhang, Xiqun Jia, Shuhua Liu, Ziyang Hu

Aim: This study aimed to investigate the causal impact of inflammatory cytokines on Sjogren's Syndrome (SS) and to identify potential biomarkers for SS clinical management using Mendelian Randomization (MR).

Materials and methods: Leveraging GWAS summary data of inflammatory cytokines and SS, we executed the first two-sample MR analysis. Genetic variants from prior GWASs associated with circulating inflammatory cytokines served as instrumental variables (IVs). Data regarding cytokines were analyzed using the Olink Target-96 Inflammation panel, synthesizing data from 14,824 participants. GWAS summary statistics for SS were procured from the UK Biobank, focusing on samples of European ancestry. To discern the causal relationship between inflammatory cytokines and SS, several MR methodologies, including inverse variance weighted (IVW) and MR-Egger regression, were applied.

Results: After rigorous IV quality control, 91 cytokines were incorporated into the MR analysis. The IVW analysis identified 8 cytokines with a positive association to SS: Axin-1 (OR 2.56, 95% CI 1.07-6.10), T-cell surface glycoprotein CD5 (OR 1.81, 95% CI 1.08-3.02), CUDP1 (OR 1.61, 95% CI 1.00-2.58), CXCL10 (OR 1.92, 95% CI 1.25-2.95), IL-4 (OR 2.18, 95% CI 1.22-3.91), IL-7 (OR 2.35, 95% CI 1.27-4.33), MCP-2 (OR 1.27, 95% CI 1.05-1.54), and TNFRSF9 (OR 1.83, 95% CI 1.03-3.24), suggesting their potential in increasing SS risk.

Conclusion: Our study conducted through MR, identified various inflammatory cytokines associated with SS risk, validating some previous research results and offering some new potential biomarkers for SS. However, these findings necessitate further research for validation and exploration of their precise role in the onset and progression of SS.

目的:本研究旨在探讨炎性细胞因子对斯尤金综合征(SS)的因果影响,并利用孟德尔随机化(MR)方法确定斯尤金综合征临床管理的潜在生物标志物:利用炎性细胞因子和SS的GWAS汇总数据,我们首次进行了双样本MR分析。先前的全球基因组研究中与循环炎症细胞因子相关的基因变异作为工具变量(IV)。有关细胞因子的数据使用 Olink Target-96 Inflammation 面板进行分析,综合了来自 14,824 名参与者的数据。SS的GWAS汇总统计数据来自英国生物库,侧重于欧洲血统的样本。为了确定炎性细胞因子与 SS 之间的因果关系,研究人员采用了几种 MR 方法,包括反方差加权(IVW)和 MR-Egger 回归:经过严格的 IV 质量控制,91 种细胞因子被纳入 MR 分析。IVW 分析确定了 8 种与 SS 呈正相关的细胞因子:Axin-1(OR 2.56,95% CI 1.07-6.10)、T 细胞表面糖蛋白 CD5(OR 1.81,95% CI 1.08-3.02)、CUDP1(OR 1.61,95% CI 1.00-2.58)、CXCL10(OR 1.92,95% CI 1.25-2.95)、IL-4(OR 2.18,95% CI 1.22-3.91)、IL-7(OR 2.35,95% CI 1.27-4.33)、MCP-2(OR 1.27,95% CI 1.05-1.54)和 TNFRSF9(OR 1.83,95% CI 1.03-3.24),表明它们可能增加 SS 风险:我们的研究通过磁共振成像发现了与 SS 风险相关的各种炎症细胞因子,验证了之前的一些研究成果,并为 SS 提供了一些新的潜在生物标志物。然而,这些发现还需要进一步研究,以验证和探索它们在 SS 发病和进展中的确切作用。
{"title":"Inflammatory cytokines and their potential role in Sjogren's syndrome risk: insights from a mendelian randomization study.","authors":"Wenbin Shi, Yuli Xu, Anan Zhang, Xiqun Jia, Shuhua Liu, Ziyang Hu","doi":"10.1186/s42358-024-00354-2","DOIUrl":"10.1186/s42358-024-00354-2","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the causal impact of inflammatory cytokines on Sjogren's Syndrome (SS) and to identify potential biomarkers for SS clinical management using Mendelian Randomization (MR).</p><p><strong>Materials and methods: </strong>Leveraging GWAS summary data of inflammatory cytokines and SS, we executed the first two-sample MR analysis. Genetic variants from prior GWASs associated with circulating inflammatory cytokines served as instrumental variables (IVs). Data regarding cytokines were analyzed using the Olink Target-96 Inflammation panel, synthesizing data from 14,824 participants. GWAS summary statistics for SS were procured from the UK Biobank, focusing on samples of European ancestry. To discern the causal relationship between inflammatory cytokines and SS, several MR methodologies, including inverse variance weighted (IVW) and MR-Egger regression, were applied.</p><p><strong>Results: </strong>After rigorous IV quality control, 91 cytokines were incorporated into the MR analysis. The IVW analysis identified 8 cytokines with a positive association to SS: Axin-1 (OR 2.56, 95% CI 1.07-6.10), T-cell surface glycoprotein CD5 (OR 1.81, 95% CI 1.08-3.02), CUDP1 (OR 1.61, 95% CI 1.00-2.58), CXCL10 (OR 1.92, 95% CI 1.25-2.95), IL-4 (OR 2.18, 95% CI 1.22-3.91), IL-7 (OR 2.35, 95% CI 1.27-4.33), MCP-2 (OR 1.27, 95% CI 1.05-1.54), and TNFRSF9 (OR 1.83, 95% CI 1.03-3.24), suggesting their potential in increasing SS risk.</p><p><strong>Conclusion: </strong>Our study conducted through MR, identified various inflammatory cytokines associated with SS risk, validating some previous research results and offering some new potential biomarkers for SS. However, these findings necessitate further research for validation and exploration of their precise role in the onset and progression of SS.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"14"},"PeriodicalIF":2.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139747573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review. 儿童期系统性红斑狼疮(cSLE)与恶性肿瘤:全国多中心系列回顾。
IF 2 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-02-06 DOI: 10.1186/s42358-024-00353-3
Matheus Zanata Brufatto, Sean Hideo Shirata Lanças, Taciana de Albuquerque Pedrosa Fernandes, Adriana Maluf Elias Sallum, Lucia Maria Arruda Campos, Ana Paula Sakamoto, Maria Teresa Terreri, Flavio Roberto Sztajnbok, Blanca Elena Rios Gomes Bica, Virginia Paes Leme Ferriani, Luciana Martins de Carvalho, Clovis Artur Almeida Silva, Claudia Saad-Magalhaes

Background: Increased malignancy frequency is well documented in adult-systemic lupus erythematosus (SLE), but with limited reports in childhood-onset SLE (cSLE) series. We explored the frequency of malignancy associated with cSLE, describing clinical and demographic characteristics, disease activity and cumulative damage, by the time of malignancy diagnosis.

Method: A retrospective case-notes review, in a nationwide cohort from 27 Pediatric Rheumatology centres, with descriptive biopsy-proven malignancy, disease activity/damage accrual, and immunosuppressive treatment were compiled in each participating centre, using a standard protocol.

Results: Of the 1757 cSLE cases in the updated cohort, 12 (0.7%) developed malignancy with median time 10 years after cSLE diagnosis. There were 91% females, median age at cSLE diagnosis 12 years, median age at malignancy diagnosis 23 years. Of all diagnosed malignancies, 11 were single-site, and a single case with concomitant multiple sites; four had haematological (0.22%) and 8 solid malignancy (0.45%). Median (min-max) SLEDAI-2 K scores were 9 (0-38), median (min-max) SLICC/ACR-DI (SDI) score were 1 (1-5) Histopathology defined 1 Hodgkin's lymphoma, 2 non-Hodgkin's lymphoma, 1 acute lymphoblastic leukaemia; 4 gastrointestinal carcinoma, 1 squamous cell carcinoma of the tongue and 1 anal carcinoma; 1 had sigmoid adenocarcinoma and 1 stomach carcinoid; 3 had genital malignancy, being 1 vulvae, 1 cervix and 1 vulvae and cervix carcinomas; 1 had central nervous system oligodendroglioma; and 1 testicle germ cell teratoma.

Conclusion: Estimated malignancy frequency of 0.7% was reported during cSLE follow up in a multicentric series. Median disease activity and cumulative damage scores, by the time of malignancy diagnoses, were high; considering that reported in adult series.

背景:成人系统性红斑狼疮(SLE)中恶性肿瘤发生率增高的情况已得到充分证实,但在儿童期发病的系统性红斑狼疮(cSLE)系列中的报道却很有限。我们探讨了儿童系统性红斑狼疮伴发恶性肿瘤的频率,描述了恶性肿瘤确诊时的临床和人口学特征、疾病活动和累积损害:方法:在27个儿科风湿病学中心的全国性队列中进行回顾性病例记录审查,每个参与中心均采用标准方案对活检证实的恶性肿瘤、疾病活动/损害累积和免疫抑制治疗进行了描述性汇编:结果:在更新队列的1757例系统性红斑狼疮病例中,有12例(0.7%)发生了恶性肿瘤,中位时间为确诊系统性红斑狼疮后10年。其中91%为女性,确诊系统性红斑狼疮的中位年龄为12岁,确诊恶性肿瘤的中位年龄为23岁。在所有确诊的恶性肿瘤中,11例为单部位恶性肿瘤,1例同时伴有多部位恶性肿瘤;4例为血液恶性肿瘤(0.22%),8例为实体恶性肿瘤(0.45%)。SLEDAI-2 K评分的中位数(最小-最大值)为9(0-38),SLICC/ACR-DI(SDI)评分的中位数(最小-最大值)为1(1-5)。组织病理学定义为1例霍奇金淋巴瘤,2例非霍奇金淋巴瘤,1例急性淋巴细胞白血病;4例胃肠道癌,1例舌鳞状细胞癌和1例肛门癌;1 例乙状结肠腺癌和 1 例胃类癌;3 例生殖器恶性肿瘤,包括 1 例外阴癌、1 例宫颈癌和 1 例外阴和宫颈癌;1 例中枢神经系统少突胶质细胞瘤;以及 1 例睾丸生殖细胞畸胎瘤。结论在一项多中心的系列研究中,狼疮随访期间的恶性肿瘤发生率估计为0.7%。在诊断出恶性肿瘤时,疾病活动度和累积损害评分的中位数都很高;考虑到成人系列中的报告,这一数字也很高。
{"title":"Childhood-onset systemic lupus erythematosus (cSLE) and malignancy: a nationwide multicentre series review.","authors":"Matheus Zanata Brufatto, Sean Hideo Shirata Lanças, Taciana de Albuquerque Pedrosa Fernandes, Adriana Maluf Elias Sallum, Lucia Maria Arruda Campos, Ana Paula Sakamoto, Maria Teresa Terreri, Flavio Roberto Sztajnbok, Blanca Elena Rios Gomes Bica, Virginia Paes Leme Ferriani, Luciana Martins de Carvalho, Clovis Artur Almeida Silva, Claudia Saad-Magalhaes","doi":"10.1186/s42358-024-00353-3","DOIUrl":"10.1186/s42358-024-00353-3","url":null,"abstract":"<p><strong>Background: </strong>Increased malignancy frequency is well documented in adult-systemic lupus erythematosus (SLE), but with limited reports in childhood-onset SLE (cSLE) series. We explored the frequency of malignancy associated with cSLE, describing clinical and demographic characteristics, disease activity and cumulative damage, by the time of malignancy diagnosis.</p><p><strong>Method: </strong>A retrospective case-notes review, in a nationwide cohort from 27 Pediatric Rheumatology centres, with descriptive biopsy-proven malignancy, disease activity/damage accrual, and immunosuppressive treatment were compiled in each participating centre, using a standard protocol.</p><p><strong>Results: </strong>Of the 1757 cSLE cases in the updated cohort, 12 (0.7%) developed malignancy with median time 10 years after cSLE diagnosis. There were 91% females, median age at cSLE diagnosis 12 years, median age at malignancy diagnosis 23 years. Of all diagnosed malignancies, 11 were single-site, and a single case with concomitant multiple sites; four had haematological (0.22%) and 8 solid malignancy (0.45%). Median (min-max) SLEDAI-2 K scores were 9 (0-38), median (min-max) SLICC/ACR-DI (SDI) score were 1 (1-5) Histopathology defined 1 Hodgkin's lymphoma, 2 non-Hodgkin's lymphoma, 1 acute lymphoblastic leukaemia; 4 gastrointestinal carcinoma, 1 squamous cell carcinoma of the tongue and 1 anal carcinoma; 1 had sigmoid adenocarcinoma and 1 stomach carcinoid; 3 had genital malignancy, being 1 vulvae, 1 cervix and 1 vulvae and cervix carcinomas; 1 had central nervous system oligodendroglioma; and 1 testicle germ cell teratoma.</p><p><strong>Conclusion: </strong>Estimated malignancy frequency of 0.7% was reported during cSLE follow up in a multicentric series. Median disease activity and cumulative damage scores, by the time of malignancy diagnoses, were high; considering that reported in adult series.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"13"},"PeriodicalIF":2.0,"publicationDate":"2024-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic polymorphism of WNT9A is functionally associated with thumb osteoarthritis in the Chinese population. 中国人群中 WNT9A 基因多态性与拇指骨关节炎的功能相关。
IF 2 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-01-29 DOI: 10.1186/s42358-023-00337-9
Jian Dai, Haitao Jiang, Zhang Cheng, Yao Li, Zhaoqi Yang, Chuan Cheng, Xiaoming Tang

Background: In a recent genome-wide association study, novel genetic variations of WNT9A were reported to be involved in the etiopathogenesis of thumb osteoarthritis (TOA) in Caucasians. Our purposes were to replicate the association of WNT9A with the development of TOA in the Chinese population and to further unveil the functional role of the risk variants.

Methods: SNP rs11588850 of WNT9A were genotyped in 953 TOA patients and 1124 healthy controls. The differences of genotype and allele distributions between the patients and healthy controls were evaluated using the Chi-square test. Luciferase Reporter Assay was performed to investigate the influence of variant on the gene expression.

Results: There was significantly lower frequency of genotype AA in TOA patients than in the controls 74.9% vs. 81.9%, p < 0.001). The frequency of allele A was remarkably lower in the patients than in the controls (86.3% vs. 90.5%, p < 0.001), with an odds ratio of 0.66 (95% CI = 0.54-0.80). Luciferase Reporter Assay showed that the construct containing mutant allele G of rs11588850 displayed 29.1% higher enhancer activity than the wild allele A construct (p < 0.05).

Conclusions: Allele G of rs11588850 was associated with the increased risk of TOA possibly via up-regulation of WNT9A expression. Further functional analysis into the regulatory role of rs11588850 in WNT9A expression can shed new light on the genetic architecture of TOA.

背景:最近的一项全基因组关联研究发现,WNT9A的新型遗传变异与白种人拇指骨关节炎(TOA)的发病机制有关。我们的目的是在中国人群中复制WNT9A与TOA发病的关联,并进一步揭示风险变异的功能作用:方法:在953名TOA患者和1124名健康对照者中对WNT9A的SNP rs11588850进行基因分型。方法:对 953 名 TOA 患者和 1124 名健康对照者的 WNT9A SNP rs11588850 进行了基因分型,并使用 Chi-square 检验评估了患者和健康对照者之间基因型和等位基因分布的差异。用荧光素酶报告试剂盒检测变异对基因表达的影响:结果:TOA 患者基因型 AA 的频率明显低于对照组,分别为 74.9% 和 81.9%(Prs11588850的等位基因G可能通过上调WNT9A的表达与TOA风险增加有关。进一步对 rs11588850 在 WNT9A 表达中的调控作用进行功能分析,可为 TOA 的遗传结构提供新的线索。
{"title":"Genetic polymorphism of WNT9A is functionally associated with thumb osteoarthritis in the Chinese population.","authors":"Jian Dai, Haitao Jiang, Zhang Cheng, Yao Li, Zhaoqi Yang, Chuan Cheng, Xiaoming Tang","doi":"10.1186/s42358-023-00337-9","DOIUrl":"10.1186/s42358-023-00337-9","url":null,"abstract":"<p><strong>Background: </strong>In a recent genome-wide association study, novel genetic variations of WNT9A were reported to be involved in the etiopathogenesis of thumb osteoarthritis (TOA) in Caucasians. Our purposes were to replicate the association of WNT9A with the development of TOA in the Chinese population and to further unveil the functional role of the risk variants.</p><p><strong>Methods: </strong>SNP rs11588850 of WNT9A were genotyped in 953 TOA patients and 1124 healthy controls. The differences of genotype and allele distributions between the patients and healthy controls were evaluated using the Chi-square test. Luciferase Reporter Assay was performed to investigate the influence of variant on the gene expression.</p><p><strong>Results: </strong>There was significantly lower frequency of genotype AA in TOA patients than in the controls 74.9% vs. 81.9%, p < 0.001). The frequency of allele A was remarkably lower in the patients than in the controls (86.3% vs. 90.5%, p < 0.001), with an odds ratio of 0.66 (95% CI = 0.54-0.80). Luciferase Reporter Assay showed that the construct containing mutant allele G of rs11588850 displayed 29.1% higher enhancer activity than the wild allele A construct (p < 0.05).</p><p><strong>Conclusions: </strong>Allele G of rs11588850 was associated with the increased risk of TOA possibly via up-regulation of WNT9A expression. Further functional analysis into the regulatory role of rs11588850 in WNT9A expression can shed new light on the genetic architecture of TOA.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"12"},"PeriodicalIF":2.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis. 白细胞介素-17 家族细胞因子在膝关节骨关节炎患者病情严重程度中的作用。
IF 2 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-01-24 DOI: 10.1186/s42358-024-00351-5
Zahra Kamiab, Hossein Khorramdelazad, Mehdi Kafi, Abdollah Jafarzadeh, Vahid Mohammadi-Shahrokhi, Zahra Bagheri-Hosseinabadi, Pooya Saeed Askari, Mitra Abbasifard

Background: Interleukin-17 (IL-17) family plays a role in the pathogenesis of knee osteoarthritis (KOA) by contributing to the inflammatory and destructive processes in the affected joint. This study aimed to measure levels of IL-17 A and IL-25 (IL-17E) in serum of KOA patients and determine their roles in the disease severity of patients.

Methods: In this, 34 patients with KOA and 30 age and sex-matched healthy subjects (HS) were enrolled. Patients were categorized based on their Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analog Scale (VAS), and Body Mass Index (BMI) scores. The enzyme-linked immunosorbent assay (ELISA) technique was employed to measure serum levels of IL-17 A and IL-25.

Results: Level of IL-25 was significantly higher (P < 0.0001) in the KOA subjects than HS. IL-17 A level was significantly higher in KOA cases with WOMAC < 40 (P < 0.0001) in comparison to HS. IL-25 level was significantly higher in the KOA cases with WOMAC < 40 (P < 0.0001) and with WOMAC ≥ 40 (P < 0.0001) compared to HS. IL-17 A concentration was significantly higher in the KOA cases with VAS < 5 (P < 0.0001) compared to HS. IL-25 level was significantly higher in the KOA cases with VAS < 5 (P < 0.0001) and with VAS ≥ 5 (P < 0.0001) in comparison to HS. KOA patients with BMI ≥ 30 had significantly higher IL-17 A and IL-25 concentration in comparison to HS.

Conclusions: The serum level of IL-25 in KOA patients is increased probably due to negative controlling feedback on inflammatory responses, which can be associated with obesity and disease activity.

背景:白细胞介素-17(IL-17)家族在膝关节骨性关节炎(KOA)的发病机制中扮演着重要角色,因为它能促进受影响关节的炎症和破坏过程。本研究旨在检测 KOA 患者血清中 IL-17 A 和 IL-25 (IL-17E) 的水平,并确定它们在患者疾病严重程度中的作用:本研究共招募了 34 名 KOA 患者和 30 名年龄与性别匹配的健康受试者(HS)。根据患者的西安大略和麦克马斯特大学骨关节炎指数(WOMAC)、视觉模拟量表(VAS)和体重指数(BMI)评分对患者进行分类。采用酶联免疫吸附试验(ELISA)技术测定血清中 IL-17 A 和 IL-25 的水平:结果:IL-25 的水平明显较高(PKOA患者血清中IL-25水平升高可能是由于炎症反应的负向控制反馈,这可能与肥胖和疾病活动有关。
{"title":"Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis.","authors":"Zahra Kamiab, Hossein Khorramdelazad, Mehdi Kafi, Abdollah Jafarzadeh, Vahid Mohammadi-Shahrokhi, Zahra Bagheri-Hosseinabadi, Pooya Saeed Askari, Mitra Abbasifard","doi":"10.1186/s42358-024-00351-5","DOIUrl":"10.1186/s42358-024-00351-5","url":null,"abstract":"<p><strong>Background: </strong>Interleukin-17 (IL-17) family plays a role in the pathogenesis of knee osteoarthritis (KOA) by contributing to the inflammatory and destructive processes in the affected joint. This study aimed to measure levels of IL-17 A and IL-25 (IL-17E) in serum of KOA patients and determine their roles in the disease severity of patients.</p><p><strong>Methods: </strong>In this, 34 patients with KOA and 30 age and sex-matched healthy subjects (HS) were enrolled. Patients were categorized based on their Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Visual Analog Scale (VAS), and Body Mass Index (BMI) scores. The enzyme-linked immunosorbent assay (ELISA) technique was employed to measure serum levels of IL-17 A and IL-25.</p><p><strong>Results: </strong>Level of IL-25 was significantly higher (P < 0.0001) in the KOA subjects than HS. IL-17 A level was significantly higher in KOA cases with WOMAC < 40 (P < 0.0001) in comparison to HS. IL-25 level was significantly higher in the KOA cases with WOMAC < 40 (P < 0.0001) and with WOMAC ≥ 40 (P < 0.0001) compared to HS. IL-17 A concentration was significantly higher in the KOA cases with VAS < 5 (P < 0.0001) compared to HS. IL-25 level was significantly higher in the KOA cases with VAS < 5 (P < 0.0001) and with VAS ≥ 5 (P < 0.0001) in comparison to HS. KOA patients with BMI ≥ 30 had significantly higher IL-17 A and IL-25 concentration in comparison to HS.</p><p><strong>Conclusions: </strong>The serum level of IL-25 in KOA patients is increased probably due to negative controlling feedback on inflammatory responses, which can be associated with obesity and disease activity.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"11"},"PeriodicalIF":2.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive 阿巴他赛与 TNF 抑制剂对 ACPA 和共享表位阳性类风湿性关节炎患者的疗效比较
IF 2.3 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-01-19 DOI: 10.1186/s42358-024-00352-4
Leslie R. Harrold, Keith Wittstock, Sheila Kelly, Xue Han, Joe Zhuo, Amy Schrader, Nicole Middaugh, Page C. Moore, Vadim Khaychuk
The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective was to examine the real-world effectiveness of abatacept versus tumor necrosis factor inhibitors (TNFi) in patients with RA who were SE and anti-cyclic citrullinated peptide antibody (anti-CCP3) positive. Abatacept or TNFi initiators who were SE + and anti-CCP3+ (> 20 U/mL) at or prior to treatment and had moderate or high CDAI score (> 10) at initiation were identified. The primary outcome was mean change in CDAI score over six months. Analyses were conducted in propensity score (PS)-trimmed and -matched populations overall and a biologic-experienced subgroup. Mixed-effects models were used. In the overall PS-trimmed (abatacept, n = 170; TNFi, n = 157) and PS-matched cohorts (abatacept, n = 111; TNFi, n = 111), there were numerically greater improvements in mean change in CDAI between abatacept and TNFi but were not statistically significant. Similar trends were seen for biologic-experienced patients, except that statistical significance was reached for mean change in CDAI in the PS-trimmed cohort (abatacept, 12.22 [95% confidence interval (95%CI) 10.13 to 14.31]; TNFi, 9.28 [95%CI 7.08 to 11.48]; p = 0.045). In this real world cohort, there were numerical improvements in efficacy outcomes with abatacept over TNFi in patients with RA who were SE + and ACPA+, similar to results from a clinical trial population The only statistically significant finding after adjusting for covariates was greater improvement in CDAI with abatacept versus TNFi in the bio-experienced PS-trimmed cohort..
HLA-DRB1共有表位(SE)是类风湿性关节炎(RA)发病和RA患者产生抗环瓜氨酸蛋白抗体(ACPA)的危险因素。我们的目的是研究阿帕他赛与肿瘤坏死因子抑制剂(TNFi)对SE和抗环瓜氨酸肽抗体(抗CCP3)阳性的RA患者的实际疗效。阿巴他赛普或 TNFi 初始患者在治疗时或治疗前为 SE + 和抗CCP3 +(> 20 U/mL),且初始时 CDAI 评分为中度或高度(> 10)。主要结果是六个月内 CDAI 评分的平均变化。对倾向得分(PS)修剪和匹配的总体人群以及有生物治疗经验的亚组进行了分析。采用了混合效应模型。在经过PS修剪的总体组群(阿帕赛普,n = 170;TNFi,n = 157)和PS匹配组群(阿帕赛普,n = 111;TNFi,n = 111)中,阿帕赛普和TNFi的CDAI平均变化在数值上有较大改善,但无统计学意义。有生物治疗经验的患者也出现了类似的趋势,但PS修饰队列中CDAI的平均变化达到了统计学意义(阿帕赛普,12.22[95%置信区间(95%CI)10.13至14.31];TNFi,9.28[95%CI 7.08至11.48];P = 0.045)。在这个真实世界的队列中,阿巴他赛普对SE+和ACPA+的RA患者的疗效结果比TNFi有数字上的改善,这与临床试验人群的结果相似。
{"title":"Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive","authors":"Leslie R. Harrold, Keith Wittstock, Sheila Kelly, Xue Han, Joe Zhuo, Amy Schrader, Nicole Middaugh, Page C. Moore, Vadim Khaychuk","doi":"10.1186/s42358-024-00352-4","DOIUrl":"https://doi.org/10.1186/s42358-024-00352-4","url":null,"abstract":"The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective was to examine the real-world effectiveness of abatacept versus tumor necrosis factor inhibitors (TNFi) in patients with RA who were SE and anti-cyclic citrullinated peptide antibody (anti-CCP3) positive. Abatacept or TNFi initiators who were SE + and anti-CCP3+ (> 20 U/mL) at or prior to treatment and had moderate or high CDAI score (> 10) at initiation were identified. The primary outcome was mean change in CDAI score over six months. Analyses were conducted in propensity score (PS)-trimmed and -matched populations overall and a biologic-experienced subgroup. Mixed-effects models were used. In the overall PS-trimmed (abatacept, n = 170; TNFi, n = 157) and PS-matched cohorts (abatacept, n = 111; TNFi, n = 111), there were numerically greater improvements in mean change in CDAI between abatacept and TNFi but were not statistically significant. Similar trends were seen for biologic-experienced patients, except that statistical significance was reached for mean change in CDAI in the PS-trimmed cohort (abatacept, 12.22 [95% confidence interval (95%CI) 10.13 to 14.31]; TNFi, 9.28 [95%CI 7.08 to 11.48]; p = 0.045). In this real world cohort, there were numerical improvements in efficacy outcomes with abatacept over TNFi in patients with RA who were SE + and ACPA+, similar to results from a clinical trial population The only statistically significant finding after adjusting for covariates was greater improvement in CDAI with abatacept versus TNFi in the bio-experienced PS-trimmed cohort..","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"12 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139498184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical significance of long non-coding RNA NORAD in rheumatoid arthritis. 长非编码 RNA NORAD 在类风湿关节炎中的临床意义。
IF 2 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-01-18 DOI: 10.1186/s42358-024-00349-z
Xueru Zhao, Weiyi Lin, Wenhui Zhou

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that may cause joint deformities and seriously affect the normal life of the patients. In order to enable patients to receive timely attention and treatment, this study developed new diagnostic markers by exploring the expression and molecular mechanism of the long non-coding RNA NORAD (NORAD) in RA.

Methods: Participants including 77 RA patients and 52 healthy persons were enrolled, and the corresponding clinical data and serum samples were obtained. The NORAD and miR-204-5p expression were detected by real-time fluorescence quantitative polymerase chain reaction (RT-qPCR). The content of inflammatory cytokines (IL-6, TNF-α) were determined through enzyme-linked immunosorbent assay (ELISA). Luciferase activity reporter assay demonstrated the association between NORAD and miR-204-5p. In addition, receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of NORAD, and Pearson's correlation analysis was applied for the correlation analysis.

Results: NORAD was enriched in RA serum with high diagnostic value. Simultaneously, IL-6 and TNF-α levels were also upregulated (P < 0.001). The C-reactive protein (CRP), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and anti-cyclic citrullinated peptide antibody (Anti-CCP) levels in RA patients were generally elevated (P < 0.001). NORAD was positively correlated with the levels of clinical indicators and inflammatory factors (P < 0.0001). Mechanistically, NORAD may affect the progression of RA by targeting and negatively regulating miR-204-5p.

Conclusions: There is a correlation between NORAD and the processes of RA, and NORAD has the potential to predict and diagnose the occurrence of RA.

背景:类风湿关节炎(RA)是一种慢性自身免疫性疾病,可导致关节畸形,严重影响患者的正常生活。为了使患者得到及时的关注和治疗,本研究通过探讨长非编码 RNA NORAD(NORAD)在 RA 中的表达和分子机制,开发了新的诊断标记物:方法:研究人员招募了 77 名 RA 患者和 52 名健康人,并获得了相应的临床数据和血清样本。采用实时荧光定量聚合酶链反应(RT-qPCR)检测 NORAD 和 miR-204-5p 的表达。炎症细胞因子(IL-6、TNF-α)的含量通过酶联免疫吸附试验(ELISA)测定。荧光素酶活性报告实验证明了 NORAD 与 miR-204-5p 之间的关联。此外,还利用接收者操作特征曲线(ROC)评估了NORAD的诊断效果,并应用皮尔逊相关分析进行了相关性分析:结果:NORAD在RA血清中富集,具有很高的诊断价值。结果:NORAD在RA血清中富集,具有很高的诊断价值,同时IL-6和TNF-α水平也上调(PNORAD与RA的发病过程存在相关性,NORAD具有预测和诊断RA的潜力。
{"title":"Clinical significance of long non-coding RNA NORAD in rheumatoid arthritis.","authors":"Xueru Zhao, Weiyi Lin, Wenhui Zhou","doi":"10.1186/s42358-024-00349-z","DOIUrl":"10.1186/s42358-024-00349-z","url":null,"abstract":"<p><strong>Background: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease that may cause joint deformities and seriously affect the normal life of the patients. In order to enable patients to receive timely attention and treatment, this study developed new diagnostic markers by exploring the expression and molecular mechanism of the long non-coding RNA NORAD (NORAD) in RA.</p><p><strong>Methods: </strong>Participants including 77 RA patients and 52 healthy persons were enrolled, and the corresponding clinical data and serum samples were obtained. The NORAD and miR-204-5p expression were detected by real-time fluorescence quantitative polymerase chain reaction (RT-qPCR). The content of inflammatory cytokines (IL-6, TNF-α) were determined through enzyme-linked immunosorbent assay (ELISA). Luciferase activity reporter assay demonstrated the association between NORAD and miR-204-5p. In addition, receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of NORAD, and Pearson's correlation analysis was applied for the correlation analysis.</p><p><strong>Results: </strong>NORAD was enriched in RA serum with high diagnostic value. Simultaneously, IL-6 and TNF-α levels were also upregulated (P < 0.001). The C-reactive protein (CRP), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and anti-cyclic citrullinated peptide antibody (Anti-CCP) levels in RA patients were generally elevated (P < 0.001). NORAD was positively correlated with the levels of clinical indicators and inflammatory factors (P < 0.0001). Mechanistically, NORAD may affect the progression of RA by targeting and negatively regulating miR-204-5p.</p><p><strong>Conclusions: </strong>There is a correlation between NORAD and the processes of RA, and NORAD has the potential to predict and diagnose the occurrence of RA.</p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"64 1","pages":"9"},"PeriodicalIF":2.0,"publicationDate":"2024-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for osteoporotic hip fracture among community-dwelling older adults: a real-world evidence study 社区老年人骨质疏松性髋部骨折的风险因素:真实世界证据研究
IF 2.3 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-01-17 DOI: 10.1186/s42358-024-00350-6
Daniela Castelo Azevedo, Leonardo Santos Hoff, Sergio Candido Kowalski, Carlos Augusto Ferreira de Andrade, Virgínia Fernandes Moça Trevisani, Ana Karla Guedes de Melo
Hip fractures in the older adults lead to increased morbidity and mortality. Although a low bone mineral density is considered the leading risk factor, it is essential to recognize other factors that could affect the risk of hip fractures. This study aims to evaluate the contribution of clinical characteristics, patient-reported outcomes, and muscle and aerobic capacity for hip fractures in community-dwelling older adults. This is a retrospective cohort study with real world-data from subjects ≥ 60 years old attending an outpatient clinic in Minas Gerais, Brazil, from May 1, 2019, to August 22, 2022. Data about clinical characteristics (multimorbidity, medications of long-term use, sedative and or tricyclic medications, number of falls), patient-reported outcomes (self-perception of health, self-report of difficulty walking, self-report of vision problems, and self-report of falls) and muscle and aerobic capacity (calf circumference, body mass index, and gait speed) were retrieved from an electronic health record. The association of each potential risk factor and hip fracture was investigated by a multivariable logistic regression analysis adjusted for age and sex. A total of 7,836 older adults were included with a median age of 80 years (IQR 72–86) and 5,702 (72.7%) were female. Hip fractures occurred in 121 (1.54%) patients. Multimorbidity was associated with an increased risk of hip fracture (OR = 1.12, 95%CI 1.06–1.18) and each episode of fall increased the chance of hip fracture by 1.7-fold (OR = 1.69, 95%CI 1.52–1.80). Patient-reported outcomes associated with increased fracture risk were regular or poor self-perception of health (OR = 1.59, 95%CI 1.06–2.37), self-report of walking difficulty (OR = 3.06, 95%CI 1.93–4.84), and self-report of falls (OR = 2.23, 95%CI 1.47–3.40). Body mass index and calf circumference were inversely associated with hip fractures (OR = 0.91, 95%CI 0.87–0.96 and OR = 0.93, 95%CI 0.88–0.97, respectively), while slow gait speed increased the chance of hip fractures by almost two-fold (OR = 1.80, 95%CI 1.22–2.66). Our study reinforces the importance of identified risk factors for hip fracture in community-dwelling older adults beyond bone mineral density and available fracture risk assessment tools. Data obtained in primary care can help physicians, other health professionals, and public health policies to identify patients at increased risk of hip fractures.
老年人髋部骨折会增加发病率和死亡率。虽然低骨矿物质密度被认为是主要的风险因素,但认识到可能影响髋部骨折风险的其他因素也很重要。本研究旨在评估社区老年人的临床特征、患者报告的结果以及肌肉和有氧运动能力对髋部骨折的影响。这是一项回顾性队列研究,采用的是2019年5月1日至2022年8月22日期间在巴西米纳斯吉拉斯州门诊就诊的≥60岁受试者的真实数据。临床特征(多病症、长期用药、镇静剂和三环类药物、跌倒次数)、患者报告结果(自我健康感知、自我报告行走困难、自我报告视力问题和自我报告跌倒)以及肌肉和有氧能力(小腿围度、体重指数和步速)等数据均来自电子健康记录。在对年龄和性别进行调整后,通过多变量逻辑回归分析研究了各潜在风险因素与髋部骨折的关系。研究共纳入 7836 名老年人,中位年龄为 80 岁(IQR 72-86),其中女性 5702 人(72.7%)。121名(1.54%)患者发生了髋部骨折。多病症与髋部骨折风险增加有关(OR = 1.12,95%CI 1.06-1.18),每次跌倒都会使髋部骨折的几率增加 1.7 倍(OR = 1.69,95%CI 1.52-1.80)。与骨折风险增加相关的患者报告结果有:经常或自我感觉健康不佳(OR = 1.59,95%CI 1.06-2.37)、自我报告行走困难(OR = 3.06,95%CI 1.93-4.84)和自我报告跌倒(OR = 2.23,95%CI 1.47-3.40)。体重指数和小腿围与髋部骨折成反比(OR = 0.91,95%CI 0.87-0.96 和 OR = 0.93,95%CI 0.88-0.97),而缓慢的步速会使髋部骨折的几率增加近两倍(OR = 1.80,95%CI 1.22-2.66)。除了骨矿密度和现有的骨折风险评估工具外,我们的研究还强调了在社区居住的老年人中识别髋部骨折风险因素的重要性。在初级保健中获得的数据可以帮助医生、其他卫生专业人员和公共卫生政策识别髋部骨折风险增加的患者。
{"title":"Risk factors for osteoporotic hip fracture among community-dwelling older adults: a real-world evidence study","authors":"Daniela Castelo Azevedo, Leonardo Santos Hoff, Sergio Candido Kowalski, Carlos Augusto Ferreira de Andrade, Virgínia Fernandes Moça Trevisani, Ana Karla Guedes de Melo","doi":"10.1186/s42358-024-00350-6","DOIUrl":"https://doi.org/10.1186/s42358-024-00350-6","url":null,"abstract":"Hip fractures in the older adults lead to increased morbidity and mortality. Although a low bone mineral density is considered the leading risk factor, it is essential to recognize other factors that could affect the risk of hip fractures. This study aims to evaluate the contribution of clinical characteristics, patient-reported outcomes, and muscle and aerobic capacity for hip fractures in community-dwelling older adults. This is a retrospective cohort study with real world-data from subjects ≥ 60 years old attending an outpatient clinic in Minas Gerais, Brazil, from May 1, 2019, to August 22, 2022. Data about clinical characteristics (multimorbidity, medications of long-term use, sedative and or tricyclic medications, number of falls), patient-reported outcomes (self-perception of health, self-report of difficulty walking, self-report of vision problems, and self-report of falls) and muscle and aerobic capacity (calf circumference, body mass index, and gait speed) were retrieved from an electronic health record. The association of each potential risk factor and hip fracture was investigated by a multivariable logistic regression analysis adjusted for age and sex. A total of 7,836 older adults were included with a median age of 80 years (IQR 72–86) and 5,702 (72.7%) were female. Hip fractures occurred in 121 (1.54%) patients. Multimorbidity was associated with an increased risk of hip fracture (OR = 1.12, 95%CI 1.06–1.18) and each episode of fall increased the chance of hip fracture by 1.7-fold (OR = 1.69, 95%CI 1.52–1.80). Patient-reported outcomes associated with increased fracture risk were regular or poor self-perception of health (OR = 1.59, 95%CI 1.06–2.37), self-report of walking difficulty (OR = 3.06, 95%CI 1.93–4.84), and self-report of falls (OR = 2.23, 95%CI 1.47–3.40). Body mass index and calf circumference were inversely associated with hip fractures (OR = 0.91, 95%CI 0.87–0.96 and OR = 0.93, 95%CI 0.88–0.97, respectively), while slow gait speed increased the chance of hip fractures by almost two-fold (OR = 1.80, 95%CI 1.22–2.66). Our study reinforces the importance of identified risk factors for hip fracture in community-dwelling older adults beyond bone mineral density and available fracture risk assessment tools. Data obtained in primary care can help physicians, other health professionals, and public health policies to identify patients at increased risk of hip fractures.","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"2 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139481902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Having chronic back pain did not impact COVID-19 outcome in a low-income population – a retrospective observational study 慢性背痛不会影响低收入人群的 COVID-19 结果--一项回顾性观察研究
IF 2.3 4区 医学 Q3 RHEUMATOLOGY Pub Date : 2024-01-11 DOI: 10.1186/s42358-023-00347-7
Antônia Celia de Castro Alcantara, Hermano Alexandre Lima Rocha, Jobson Lopes de Oliveira, Xenofon Baraliakos, Francisco Airton Castro Rocha
Chronic back pain (CBP) is a major cause of years lived with disability. Social inequalities increase the prevalence and burden of CBP. Management of CBP was affected by restricted access to non-pharmacological treatments and outdoor activities during COVID-19 pandemic. To determine the prevalence of CBP among patients with COVID-19 as well as the impact of having CBP in COVID-19 outcome in our low-income population. Retrospective cohort of individuals with confirmed COVID diagnosis from May 2020 - March 2021, at Hospital Regional UNIMED (HRU) in Fortaleza, Ceará, Brazil. Data included comorbidities and household income. Among 1,487 patients, 600 (40.3%) were classified as having CBP. Mean age as well as income were similar in CBP and non-CBP groups, with more women in the CBP group. Hypertension and asthma, but not diabetes, were more prevalent in those with CBP. Need for emergency care, hospitalization, and admission to intensive care unit were similar regardless of having CBP. Dyspnea was more common in CBP vs. non-CBP groups, with 48.8% vs. 39.4% percentages, respectively (p = 0.0004). Having CBP prior to COVID did not impact the acute clinical outcome of COVID individuals of a low-income population.
慢性背痛(CBP)是导致残疾生活年限的一个主要原因。社会不平等增加了慢性背痛的发病率和负担。在 COVID-19 大流行期间,非药物治疗和户外活动受到限制,从而影响了对 CBP 的管理。确定 CBP 在 COVID-19 患者中的患病率,以及 CBP 对低收入人群 COVID-19 结果的影响。对巴西塞阿拉州福塔莱萨地区 UNIMED 医院(HRU)2020 年 5 月至 2021 年 3 月期间确诊为 COVID 的患者进行回顾性队列研究。数据包括合并症和家庭收入。在 1487 名患者中,有 600 人(40.3%)被归类为 CBP 患者。CBP 组和非 CBP 组的平均年龄和收入相似,但 CBP 组中女性较多。高血压和哮喘在 CBP 患者中发病率较高,但糖尿病患者不多。无论是否患有 CBP,急诊、住院和入住重症监护室的需求都相似。呼吸困难在 CBP 组和非 CBP 组中更为常见,分别占 48.8% 和 39.4%(P = 0.0004)。在 COVID 之前患有 CBP 不会影响低收入人群 COVID 患者的急性临床结果。
{"title":"Having chronic back pain did not impact COVID-19 outcome in a low-income population – a retrospective observational study","authors":"Antônia Celia de Castro Alcantara, Hermano Alexandre Lima Rocha, Jobson Lopes de Oliveira, Xenofon Baraliakos, Francisco Airton Castro Rocha","doi":"10.1186/s42358-023-00347-7","DOIUrl":"https://doi.org/10.1186/s42358-023-00347-7","url":null,"abstract":"Chronic back pain (CBP) is a major cause of years lived with disability. Social inequalities increase the prevalence and burden of CBP. Management of CBP was affected by restricted access to non-pharmacological treatments and outdoor activities during COVID-19 pandemic. To determine the prevalence of CBP among patients with COVID-19 as well as the impact of having CBP in COVID-19 outcome in our low-income population. Retrospective cohort of individuals with confirmed COVID diagnosis from May 2020 - March 2021, at Hospital Regional UNIMED (HRU) in Fortaleza, Ceará, Brazil. Data included comorbidities and household income. Among 1,487 patients, 600 (40.3%) were classified as having CBP. Mean age as well as income were similar in CBP and non-CBP groups, with more women in the CBP group. Hypertension and asthma, but not diabetes, were more prevalent in those with CBP. Need for emergency care, hospitalization, and admission to intensive care unit were similar regardless of having CBP. Dyspnea was more common in CBP vs. non-CBP groups, with 48.8% vs. 39.4% percentages, respectively (p = 0.0004). Having CBP prior to COVID did not impact the acute clinical outcome of COVID individuals of a low-income population.","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"261 1","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139421864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Rheumatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1